Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature
Authors:
- 4 January 2022
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 21 (4) , 103034
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Cryoglobulinemia vasculitisCurrent Opinion in Rheumatology, 2013
- Using Rituximab Plus Fludarabine and Cyclophosphamide as a Treatment for Refractory Mixed Cryoglobulinemia Associated With LymphomaArthritis Care & Research, 2012
- Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas surveyBlood, 2012
- A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitisArthritis & Rheumatism, 2011
- A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus–associated cryoglobulinemic vasculitisArthritis & Rheumatism, 2011
- Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literatureAutoimmunity Reviews, 2011
- Prognostic factors in patients with hepatitis C virus infection and systemic vasculitisArthritis & Rheumatism, 2011
- CryoglobulinemiaMedicine, 2001
- Mixed cryoglobulinemia: Clinical aspects and long-term follow-up of 40 patientsThe American Journal of Medicine, 1980
- Biologic and clinical significance of cryoglobulinsThe American Journal of Medicine, 1974